Statistical analyzes
Treatment arms were compared for changes from baseline in HbA1c, FPG, and 2 h‐PPG at week 24 using a mixed effects analysis of covariance model for repeated measures in all patients and all subgroups. All data, including those collected after discontinuation of the study treatment and use of rescue treatment, were included. The observed change from baseline at each scheduled post‐baseline visit was the dependent variable. The model included the baseline value as a covariate with fixed factors for the baseline HbA1c category, visits, baseline‐by‐visit, and treatment‐by‐visit interactions. Least squares mean (LSM) differences between arms (each chiglitazar dose vs. sitagliptin) and 95% confidence intervals (CIs) were estimated, a value of 